Here's a deal that's all about robots helping doctors, and maybe helping investors too. On Wednesday, Stereotaxis Inc. (STXS) said it's buying Robocath, a venture-backed company that makes robotic technologies for interventional cardiology and neurointerventions. Think of it as a surgical robotics firm deciding to double down on the future of minimally invasive procedures.
Stereotaxis already offers robotics for endovascular intervention, so this acquisition is basically a way to supercharge its capabilities. The big idea? It's supposed to speed up Stereotaxis's entry into some very large interventional markets—we're talking markets worth tens of billions of dollars each year. That's the kind of opportunity that gets a company's attention.
The strategic move is meant to bolster Stereotaxis's position in the robotic technologies market, and it could drive some serious revenue growth as the company folds Robocath's solutions into its own offerings. How much growth? Well, they're expecting the combined setup to bring in roughly $2 million in annual revenue in the first year after the deal closes. Not a game-changer overnight, but a start. The transaction itself is projected to hit breakeven by the third year post-acquisition, thanks to commercial and operational synergies.
So, what's next? Stereotaxis plans to accelerate the development of Robocath's next-generation system and go after regulatory submissions in the United States and Europe within the next two years. The combined platform will integrate both companies' robotic systems to offer a seamless joint solution for cardiology and neurointerventions. Down the line, they're looking to expand applications into electrophysiology too.
Now, let's talk money. The deal includes an upfront payment of $20 million, plus additional contingent payments of up to $25 million tied to regulatory and commercial milestones. It's expected to close in mid-2026. As of December 31, 2025, Stereotaxis had cash and cash equivalents of $13.4 million and no debt, which gives you a sense of the financial footing here.
On the technical side, Stereotaxis is currently trading within its 52-week range, with a high of $3.59 and a low of $1.67, sitting closer to the lower end. The stock is trading 8.4% above its 20-day simple moving average and 1.5% above its 50-day SMA, hinting at a short-term bullish trend. But it's still facing resistance from the longer-term 100-day and 200-day SMAs, trading 8.9% and 17.8% below them, respectively. The relative strength index is at 57.91, indicating neutral momentum—so not overbought or oversold. The moving average convergence divergence shows a bullish signal, with the MACD line above the signal line, suggesting potential upward momentum soon.
Key resistance sits at $2.50, a level where selling pressure has popped up before, while key support is at $1.75, a spot that might attract buyers if tested. As for the stock price, Stereotaxis shares were up 0.99% at $2.05 during premarket trading on Wednesday, according to market data.
